These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21779641)

  • 21. Euro MPs refuse to approve medicines agency's accounts until they tighten rules on conflicts of interest.
    Watson R
    BMJ; 2012 May; 344():e3495. PubMed ID: 22597355
    [No Abstract]   [Full Text] [Related]  

  • 22. Using evidence-based accreditation standards to promote continuous quality improvement: the experiences of the San Mateo County Human Services Agency.
    Winship K; Lee ST
    J Evid Based Soc Work; 2012; 9(1-2):68-86. PubMed ID: 22409613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The emerging role of benefit-cost analysis in the regulatory process at EPA.
    Luken RA
    Environ Health Perspect; 1985 Oct; 62():373-9. PubMed ID: 3936707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limits to neoliberal reforms in the health sector: the case of pharmaceutical management in New Zealand.
    Dew K; Davis A
    Int J Health Serv; 2014; 44(1):137-53. PubMed ID: 24684088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The Brazilian National Health Surveillance Agency performance evaluation at the management contract model].
    Moreira EM; Costa EA
    Cien Saude Colet; 2010 Nov; 15 Suppl 3():3381-91. PubMed ID: 21120326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Regulatory science in public health: What are we talking about?].
    Camadro M; Benamouzig D; Barouki R; Trouvin JH; Astagneau P
    Sante Publique; 2018; 30(2):187-196. PubMed ID: 30148306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Learning about knowledge management for improving environmental impact assessment in a government agency: the Western Australian experience.
    Sánchez LE; Morrison-Saunders A
    J Environ Manage; 2011 Sep; 92(9):2260-71. PubMed ID: 21592648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
    Mittermayer R; Huić M; Mestrović J
    Acta Med Croatica; 2010 Dec; 64(5):425-34. PubMed ID: 21692267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Posting Peculiarity.
    Ulsh BA; Bradley E
    Health Phys; 2017 May; 112(5):492-493. PubMed ID: 28350706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies.
    Lexchin J; O'Donovan O
    Soc Sci Med; 2010 Mar; 70(5):643-7. PubMed ID: 19782458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk and benefit in environmental law.
    Ricci PF; Molton LS
    Science; 1981 Dec; 214(4525):1096-100. PubMed ID: 7302580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expert consensus (SBC/SBHCI) on the use of drug-eluting stents: recommendations of the Brazilian society of interventional cardiology/ Brazilian society of cardiology for the Brazilian public single healthcare system.
    Lima VC; Mattos LA; Caramori PR; Perin MA; Mangione JA; Machado BM; Coelho WM; Bueno RR
    Arq Bras Cardiol; 2006 Oct; 87(4):e162-7. PubMed ID: 17128305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. True grit. One agency's story.
    Herget JB
    Caring; 1998 Jun; 17(6):46-9. PubMed ID: 10181306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The National Health Agency: the challenge of a unified national program rejecting technocratic and centralized approaches].
    Courrèges C; Lopez A
    Sante Publique; 2012; 24(3):229-40. PubMed ID: 23043697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Executive Order 13,422, OMB's good guidance practices, and implications for health rulemaking and guidance.
    Harris MD
    J Health Life Sci Law; 2007; 1(1):127, 129-50. PubMed ID: 18610733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [National Agency for Medicaments (ANAMED, Chile): an opportunity not to be missed].
    Espinoza S MA; Cabieses B
    Rev Med Chil; 2011 Dec; 139(12):1624-5. PubMed ID: 22446712
    [No Abstract]   [Full Text] [Related]  

  • 37. Product-based Safety Certification for Medical Devices Embedded Software.
    Neto JA; Figueiredo Damásio J; Monthaler P; Morais M
    Stud Health Technol Inform; 2015; 216():227-31. PubMed ID: 26262044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. International cooperation in the field of space life sciences: European Space Agency's (ESA) perspectives.
    Oser H
    ASGSB Bull; 1989 Aug; 2():90-2. PubMed ID: 11592293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The challenges of nanotechnology for the sanitary vigilance of medication].
    Batista Ade J; Pepe VL
    Cien Saude Colet; 2014 Jul; 19(7):2105-14. PubMed ID: 25014290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug regulatory authorities in South America: an analysis based on organizational rules].
    Sandri MM; De Seta MH; Luiza VL
    Rev Panam Salud Publica; 2013 Sep; 34(3):169-75. PubMed ID: 24233109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.